Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer–A Single Institution Experience-Reference-Cited by-同舟云学术

Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer–A Single Institution Experience

Published:2018-08-06 Issue:2 Volume:11 Page:147-152
ISSN:1874-4710
Container-title:Current Radiopharmaceuticals
language:en
Short-container-title:CRP

Author:

Kairemo Kalevi¹,Milton Denai R.²,Etchebehere Elba¹,Rohren Eric M.¹,Macapinlac Homer A.¹

Affiliation:

1. Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, United States

2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, United States

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology,Radiology, Nuclear Medicine and imaging

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world safety and effectiveness of radium‐223 in patients with metastatic castration‐resistant prostate cancer: Interim analyses of the prospective, observational RAPIT study;International Journal of Cancer;2024-06-26

2. Radiomics and theranostics with molecular and metabolic probes in prostate cancer: toward a personalized approach;Expert Review of Molecular Diagnostics;2023-03-04

3. A Retrospective Comparative Study of Sodium Fluoride Na18F-PET/CT and 68Ga-PSMA-11 PET/CT in the Bone Metastases of Prostate Cancer Using a Volumetric 3-D Radiomic Analysis;Life;2022-11-25

4. Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227;Frontiers in Medicine;2022-11-15

5. Targeted Radionuclide Therapy for Bone Metastasis;Nuclear Oncology;2022